|
CU22545A1
(es)
|
1994-11-18 |
1999-03-31 |
Centro Inmunologia Molecular |
Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US6022958A
(en)
|
1986-08-13 |
2000-02-08 |
Bayer Corporation |
cDNAs coding for members of the carcinoembryonic antigen family
|
|
US5057540A
(en)
|
1987-05-29 |
1991-10-15 |
Cambridge Biotech Corporation |
Saponin adjuvant
|
|
GB8800078D0
(en)
|
1988-01-05 |
1988-02-10 |
Ciba Geigy Ag |
Novel antibodies
|
|
US5162504A
(en)
|
1988-06-03 |
1992-11-10 |
Cytogen Corporation |
Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
|
|
AU4128089A
(en)
|
1988-09-15 |
1990-03-22 |
Rorer International (Overseas) Inc. |
Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
|
|
NZ230747A
(en)
|
1988-09-30 |
1992-05-26 |
Bror Morein |
Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
|
|
CA2017507C
(en)
|
1989-05-25 |
1996-11-12 |
Gary Van Nest |
Adjuvant formulation comprising a submicron oil droplet emulsion
|
|
HUT60768A
(en)
|
1990-03-16 |
1992-10-28 |
Sandoz Ag |
Process for producing cd25 fixing molecules
|
|
GB9014932D0
(en)
|
1990-07-05 |
1990-08-22 |
Celltech Ltd |
Recombinant dna product and method
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US5955075A
(en)
|
1992-03-11 |
1999-09-21 |
Institute Of Virology, Slovak Academy Of Sciences |
Method of inhibiting tumor growth using antibodies to MN protein
|
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
US5472693A
(en)
|
1993-02-16 |
1995-12-05 |
The Dow Chemical Company |
Family of anti-carcinoembryonic antigen chimeric antibodies
|
|
AUPM873294A0
(en)
|
1994-10-12 |
1994-11-03 |
Csl Limited |
Saponin preparations and use thereof in iscoms
|
|
US5686292A
(en)
|
1995-06-02 |
1997-11-11 |
Genentech, Inc. |
Hepatocyte growth factor receptor antagonist antibodies and uses thereof
|
|
US6824993B2
(en)
|
1995-06-06 |
2004-11-30 |
Human Genome Sciences, Inc. |
Antibodies that bind human prostate specific G-protein receptor HPRAJ70
|
|
WO1997034636A1
(en)
|
1996-03-20 |
1997-09-25 |
Immunomedics, Inc. |
Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
|
|
US6150508A
(en)
|
1996-03-25 |
2000-11-21 |
Northwest Biotherapeutics, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
|
US7011812B1
(en)
|
1996-05-03 |
2006-03-14 |
Immunomedics, Inc. |
Targeted combination immunotherapy of cancer and infectious diseases
|
|
AU719513B2
(en)
|
1996-05-04 |
2000-05-11 |
Astrazeneca Ab |
Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system
|
|
US6107090A
(en)
|
1996-05-06 |
2000-08-22 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
|
|
US6590088B1
(en)
|
1996-07-19 |
2003-07-08 |
Human Genome Sciences, Inc. |
CD33-like protein
|
|
US6653104B2
(en)
|
1996-10-17 |
2003-11-25 |
Immunomedics, Inc. |
Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
|
|
US6417337B1
(en)
|
1996-10-31 |
2002-07-09 |
The Dow Chemical Company |
High affinity humanized anti-CEA monoclonal antibodies
|
|
US5989604A
(en)
|
1996-12-19 |
1999-11-23 |
Adore-A-Pet, Ltd. |
Xylitol-containing non-human foodstuff and method
|
|
US5942602A
(en)
|
1997-02-13 |
1999-08-24 |
Schering Aktiengessellschaft |
Growth factor receptor antibodies
|
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
|
ATE473242T1
(de)
|
1998-05-20 |
2010-07-15 |
Immunomedics Inc |
Therapeutische mittel welche einen bispezifischen anti-hla class ii invariant chain x anti-pathogen antikörper enthalten
|
|
US7312318B2
(en)
|
2002-03-01 |
2007-12-25 |
Immunomedics, Inc. |
Internalizing anti-CD74 antibodies and methods of use
|
|
NZ517331A
(en)
|
1999-07-29 |
2004-02-27 |
Medarex Inc |
Human monoclonal antibodies to prostate specific membrane antigen and a transgenic mouse to produce the antibody
|
|
US6716966B1
(en)
|
1999-08-18 |
2004-04-06 |
Altarex Corp. |
Therapeutic binding agents against MUC-1 antigen and methods for their use
|
|
US7147850B2
(en)
|
1999-08-18 |
2006-12-12 |
Altarex Medical Corp. |
Therapeutic binding agents against MUC-1 antigen and methods for their use
|
|
ATE419354T1
(de)
|
2000-02-25 |
2009-01-15 |
Us Gov Health & Human Serv |
Scfv-moleküle gegen egfrviii mit verbesserter zytotoxizität und ausbeute, darauf basierte immuntoxine, und verfahren zur deren verwendung
|
|
US7163681B2
(en)
|
2000-08-07 |
2007-01-16 |
Centocor, Inc. |
Anti-integrin antibodies, compositions, methods and uses
|
|
CA2418014C
(en)
|
2000-08-08 |
2014-01-21 |
Immunomedics, Inc. |
Immunotherapy for chronic myelocytic leukemia
|
|
JP2005508839A
(ja)
|
2001-03-29 |
2005-04-07 |
ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド |
ペプチドおよびｍｕｃ１タンパク質に対する抗体
|
|
JP2004536578A
(ja)
|
2001-03-30 |
2004-12-09 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
腫瘍ターゲティング用の抗−ｍｕｃ−１単鎖抗体
|
|
US7183388B2
(en)
|
2001-03-30 |
2007-02-27 |
The Regents Of The University Of California |
Anti-MUC-1 single chain antibodies for tumor targeting
|
|
WO2002098897A2
(en)
|
2001-06-01 |
2002-12-12 |
Cornell Research Foundation, Inc. |
Modified antibodies to prostate-specific membrane antigen and uses thereof
|
|
AU2002315411A1
(en)
|
2001-06-21 |
2003-01-08 |
Glycotech Corporation |
Detection and treatment of prostate cancer
|
|
NZ571596A
(en)
|
2001-08-03 |
2010-11-26 |
Glycart Biotechnology Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
|
AR036833A1
(es)
|
2001-10-18 |
2004-10-06 |
Bayer Corp |
Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular.
|
|
JP5355839B2
(ja)
|
2001-10-23 |
2013-11-27 |
ピーエスエムエー デベロプメント カンパニー， エル．エル．シー． |
Ｐｓｍａ抗体およびタンパク質マルチマー
|
|
AU2002351208A1
(en)
|
2001-12-03 |
2003-06-17 |
Abgenix, Inc. |
Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
|
|
CA2474616A1
(en)
|
2002-01-28 |
2003-08-07 |
Medarex, Inc. |
Human monoclonal antibodies to prostate specific membrane antigen (psma)
|
|
HUE026218T2
(en)
|
2002-02-21 |
2016-05-30 |
Inst Virology |
MN / CA IX-Specific Monoclonal Antibodies and Methods for MN / CA IX Deficient Mice
|
|
US20090162382A1
(en)
|
2002-03-01 |
2009-06-25 |
Bernett Matthew J |
Optimized ca9 antibodies and methods of using the same
|
|
NZ535425A
(en)
|
2002-03-13 |
2008-05-30 |
Biogen Idec Inc |
Anti-alphavbeta6 antibodies
|
|
EP2289942B1
(en)
|
2002-04-10 |
2013-07-31 |
Genentech, Inc. |
Anti-HER2 antibody variants
|
|
CA2491017A1
(en)
|
2002-07-03 |
2004-01-15 |
Immunogen, Inc. |
Antibodies to non-shed muc1 and muc16, and uses thereof
|
|
SE0202110D0
(sv)
|
2002-07-05 |
2002-07-05 |
Isconova Ab |
Iscom preparation and use thereof
|
|
US20090252738A1
(en)
|
2002-08-23 |
2009-10-08 |
Novartis Vaccines And Diagnostics, Inc. |
Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix
|
|
US7541440B2
(en)
|
2002-09-30 |
2009-06-02 |
Immunomedics, Inc. |
Chimeric, human and humanized anti-granulocyte antibodies and methods of use
|
|
CN101972478B
(zh)
|
2002-10-08 |
2012-10-31 |
免疫医疗公司 |
抗体治疗
|
|
ZA200503075B
(en)
|
2002-11-07 |
2006-09-27 |
Immunogen Inc |
Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
|
|
US7438907B2
(en)
|
2002-11-15 |
2008-10-21 |
Genmab A/S |
Human monoclonal antibodies against CD25
|
|
EP2336189A1
(en)
|
2003-01-28 |
2011-06-22 |
Proscan RX Pharma |
Prostate cancer diagnosis and treatment
|
|
MXPA05008222A
(es)
|
2003-01-31 |
2005-10-05 |
Immunomedics Inc |
Metodos y composiciones para administrar agentes terapeuticos y de diagnostico.
|
|
BRPI0407446A
(pt)
|
2003-02-13 |
2006-01-31 |
Pharmacia Corp |
Anticorpos para c-met para o tratamento de cânceres
|
|
WO2005001486A1
(en)
|
2003-06-06 |
2005-01-06 |
Genentech, Inc. |
Modulating the interaction between hgf beta chain and c-met
|
|
KR20130065723A
(ko)
|
2003-06-27 |
2013-06-19 |
암젠 프레몬트 인코포레이티드 |
상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
|
|
SE0301998D0
(sv)
|
2003-07-07 |
2003-07-07 |
Isconova Ab |
Quil A fraction with low toxicity and use thereof
|
|
CA2534639C
(en)
|
2003-07-31 |
2013-07-30 |
Immunomedics, Inc. |
Anti-cd19 antibodies
|
|
US7902338B2
(en)
|
2003-07-31 |
2011-03-08 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
|
CA2548282A1
(en)
|
2003-12-11 |
2005-06-30 |
Genentech, Inc. |
Methods and compositions for inhibiting c-met dimerization and activation
|
|
CA2556025A1
(en)
|
2004-02-23 |
2005-09-09 |
Sugen, Inc. |
Method of treating abnormal cell growth using c-met and m-tor inhibitors
|
|
KR101205289B1
(ko)
|
2004-07-02 |
2012-11-27 |
빌렉스 아게 |
Ｇ-250 발현 종양의 개선된 보조제 요법
|
|
DK1771482T3
(da)
|
2004-07-22 |
2014-10-20 |
Genentech Inc |
HER2-antistofsammensætning
|
|
CA2575402A1
(en)
|
2004-08-05 |
2006-02-09 |
Genentech, Inc. |
Humanized anti-cmet antagonists
|
|
WO2006044643A2
(en)
|
2004-10-15 |
2006-04-27 |
Seattle Genetics, Inc. |
Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
AU2005304031B2
(en)
|
2004-11-09 |
2009-04-23 |
Philogen Spa |
Antibodies against tenascin-C
|
|
DE602005022928D1
(de)
|
2004-11-30 |
2010-09-23 |
Abgenix Inc |
Antikörper gegen gpnmb und ihre verwendungen
|
|
CN101160324B
(zh)
|
2005-02-18 |
2013-04-24 |
米德列斯公司 |
缺乏岩藻糖残基的抗前列腺特异性膜抗原(psma)单克隆抗体
|
|
NZ561211A
(en)
|
2005-03-25 |
2011-03-31 |
Genentech Inc |
Methods and compositions for modulating hyperstabilized C-met
|
|
PT2343320T
(pt)
|
2005-03-25 |
2018-01-23 |
Gitr Inc |
Anticorpos anti-gitr e as suas utilizações
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
CN104072614B
(zh)
|
2005-07-08 |
2017-04-26 |
生物基因Ma公司 |
抗-αvβ6 抗体及其用途
|
|
EP1928912A4
(en)
|
2005-09-07 |
2010-02-24 |
Medimmune Inc |
EPH ANTI-RECEPTOR ANTIBODIES CONJUGATED TO TOXINS
|
|
SI1934174T1
(sl)
|
2005-10-07 |
2011-08-31 |
Exelixis Inc |
Inhibitorji MEK in postopki za njihovo uporabo
|
|
US8101727B2
(en)
|
2006-03-30 |
2012-01-24 |
Novartis Ag |
Compositions and methods of use for antibodies of c-Met
|
|
RU2429014C2
(ru)
|
2006-03-31 |
2011-09-20 |
Массачусетс Инститьют Оф Текнолоджи |
Лечение опухолей, экспрессирующих мутантные рецепторы egf
|
|
CA2652703C
(en)
|
2006-06-07 |
2018-08-28 |
Bioalliance C.V. |
Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
|
|
EP2064244B1
(en)
|
2006-08-03 |
2019-06-05 |
MedImmune Limited |
ANTIBODIES DIRECTED TO alphaVbeta6 AND USES THEREOF
|
|
PL2383297T3
(pl)
|
2006-08-14 |
2013-06-28 |
Xencor Inc |
Zoptymalizowane przeciwciała ukierunkowane na CD19
|
|
CN101535332A
(zh)
|
2006-10-31 |
2009-09-16 |
免疫基因公司 |
用于提高抗体产量的方法
|
|
US8591886B2
(en)
|
2007-07-12 |
2013-11-26 |
Gitr, Inc. |
Combination therapies employing GITR binding molecules
|
|
EP2014681A1
(en)
|
2007-07-12 |
2009-01-14 |
Pierre Fabre Medicament |
Novel antibodies inhibiting c-met dimerization, and uses thereof
|
|
DK2211904T3
(en)
|
2007-10-19 |
2016-10-24 |
Seattle Genetics Inc |
Cd19-binding agents and uses thereof
|
|
WO2009056342A1
(en)
|
2007-11-02 |
2009-05-07 |
Wilex Ag |
Binding epitopes for g250 antibody
|
|
HUE026846T2
(en)
|
2007-12-18 |
2016-08-29 |
Bioalliance Cv |
Antibodies to Recognize Carbohydrate-Containing Epitope on CD43 and CEA Expressed on Cancer Cells and Procedures for their Use
|
|
WO2009086072A2
(en)
|
2007-12-21 |
2009-07-09 |
Genentech, Inc. |
Therapy of rituximab-refractory rheumatoid arthritis patients
|
|
CN101965366B
(zh)
|
2007-12-26 |
2016-04-27 |
生物测试股份公司 |
靶向cd138的免疫缀合物及其应用
|
|
US9221914B2
(en)
|
2007-12-26 |
2015-12-29 |
Biotest Ag |
Agents targeting CD138 and uses thereof
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
RU2531754C2
(ru)
|
2008-04-11 |
2014-10-27 |
ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US |
Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
|
|
CN102159243B
(zh)
|
2008-07-21 |
2015-08-19 |
免疫医疗公司 |
用于改良的治疗特征的抗体的结构变体
|
|
AU2009288730B2
(en)
|
2008-08-25 |
2013-06-20 |
Amplimmune, Inc. |
Compositions of PD-1 antagonists and methods of use
|
|
EP2361263A1
(en)
|
2008-10-31 |
2011-08-31 |
Abbott Biotherapeutics Corp. |
Use of anti-cs1 antibodies for treatment of rare lymphomas
|
|
WO2010051502A2
(en)
|
2008-10-31 |
2010-05-06 |
Biogen Idec Ma Inc. |
Light targeting molecules and uses thereof
|
|
PA8849001A1
(es)
|
2008-11-21 |
2010-06-28 |
Lilly Co Eli |
Anticuerpos de c-met
|
|
US8545839B2
(en)
|
2008-12-02 |
2013-10-01 |
Pierre Fabre Medicament |
Anti-c-Met antibody
|
|
AR074439A1
(es)
|
2008-12-02 |
2011-01-19 |
Pf Medicament |
Anticuerpo anti-cmet (receptor c-met)
|
|
CA2761120A1
(en)
|
2009-05-06 |
2010-11-11 |
Biotest Ag |
Uses of immunoconjugates targeting cd138
|
|
EP2427490A1
(en)
|
2009-05-07 |
2012-03-14 |
Novartis AG |
Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both
|
|
KR101790802B1
(ko)
|
2009-09-03 |
2017-10-27 |
머크 샤프 앤드 돔 코포레이션 |
항-ｇｉｔｒ 항체
|
|
EP2478110B1
(en)
|
2009-09-16 |
2016-01-06 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
|
US20110028129A1
(en)
|
2009-10-13 |
2011-02-03 |
Hutchison James W |
Proximity Triggered Profile-Based Wireless Matching
|
|
KR101671378B1
(ko)
|
2009-10-30 |
2016-11-01 |
삼성전자 주식회사 |
ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
|
|
KR101748707B1
(ko)
|
2009-11-27 |
2017-06-20 |
삼성전자주식회사 |
ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트
|
|
EP2513148B1
(en)
|
2009-12-16 |
2016-08-31 |
AbbVie Biotherapeutics Inc. |
Anti-her2 antibodies and their uses
|
|
US8609095B2
(en)
|
2010-03-04 |
2013-12-17 |
Symphogen A/S |
Anti-HER2 antibodies and compositions
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン，エルエルシー |
Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
|
|
PL2904011T3
(pl)
|
2012-10-02 |
2018-01-31 |
Bristol Myers Squibb Co |
Połączenie przeciwciał anty-kir i przeciwciał anty-pd-1 w leczeniu raka
|
|
EP2906296B1
(en)
|
2012-10-12 |
2018-03-21 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine-antibody conjugates
|
|
CN112552401B
(zh)
|
2013-09-13 |
2023-08-25 |
广州百济神州生物制药有限公司 |
抗pd1抗体及其作为治疗剂与诊断剂的用途
|
|
JP6595458B2
(ja)
|
2013-09-20 |
2019-10-23 |
ブリストル−マイヤーズ スクイブ カンパニー |
腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ
|
|
WO2015095423A2
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
KR20160146747A
(ko)
|
2014-03-31 |
2016-12-21 |
제넨테크, 인크. |
항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
|
|
CN106604742B
(zh)
|
2014-07-03 |
2019-01-11 |
百济神州有限公司 |
抗pd-l1抗体及其作为治疗剂及诊断剂的用途
|
|
RU2715038C2
(ru)
|
2014-07-11 |
2020-02-21 |
Дженентек, Инк. |
Антитела анти-pd-l1 и способы их диагностического применения
|
|
EP3563870A1
(en)
|
2014-07-15 |
2019-11-06 |
F. Hoffmann-La Roche AG |
Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
|
TW201619200A
(zh)
|
2014-10-10 |
2016-06-01 |
麥迪紐有限責任公司 |
人類化抗－ｏｘ４０抗體及其用途
|
|
WO2016073380A1
(en)
|
2014-11-03 |
2016-05-12 |
Genentech, Inc. |
Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
|
SG10201807625PA
(en)
|
2014-11-17 |
2018-10-30 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
CN107148285B
(zh)
|
2014-11-25 |
2022-01-04 |
Adc治疗股份有限公司 |
吡咯并苯并二氮杂䓬-抗体缀合物
|
|
US10983128B2
(en)
|
2015-02-05 |
2021-04-20 |
Bristol-Myers Squibb Company |
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
|
|
GB201506405D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
KR20250004095A
(ko)
|
2015-04-17 |
2025-01-07 |
브리스톨-마이어스 스큅 컴퍼니 |
항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
|
|
SG11201708804WA
(en)
|
2015-05-07 |
2017-11-29 |
Agenus Inc |
Anti-ox40 antibodies and methods of use thereof
|
|
GB201507827D0
(en)
*
|
2015-05-07 |
2015-06-17 |
Adc Therapeutics Sarl |
Diagnostic test
|
|
US20160347848A1
(en)
|
2015-05-28 |
2016-12-01 |
Medimmune Limited |
Therapeutic combinations and methods for treating neoplasia
|
|
MX2017015260A
(es)
|
2015-06-03 |
2018-02-19 |
Squibb Bristol Myers Co |
Anticuerpos anti receptor de factor de necrosis tumoral inducible por glucocorticoide (gitr) para diagnostico del cancer.
|
|
CN107922500A
(zh)
|
2015-06-29 |
2018-04-17 |
洛克菲勒大学 |
具有增强的激动剂活性的抗cd40抗体
|
|
GB201513607D0
(en)
*
|
2015-07-31 |
2015-09-16 |
Feingold Jay M |
Pyrrolobenzodiazepine-antibody conjugates
|
|
CA2955184A1
(en)
|
2016-01-25 |
2017-07-25 |
Pfizer Inc. |
Combination of an ox40 agonist and a 4-1bb agonist for treating cancer
|
|
CN109641051A
(zh)
*
|
2016-06-17 |
2019-04-16 |
美真达治疗公司 |
用于耗尽细胞的组合物和方法
|
|
EP3525829A1
(en)
*
|
2016-10-11 |
2019-08-21 |
Medimmune Limited |
Antibody-drug conjugates with immune-mediated therapy agents
|
|
EP3612236A1
(en)
*
|
2017-04-20 |
2020-02-26 |
ADC Therapeutics SA |
Combination therapy with an anti-cd25 antibody-drug conjugate
|
|
BR112019026498A2
(pt)
*
|
2017-06-14 |
2020-07-14 |
Adc Therapeutics Sa |
regimes de dosagem para a administração de um adc anti-cd25
|